CA1182811A - Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications - Google Patents
Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applicationsInfo
- Publication number
- CA1182811A CA1182811A CA000394587A CA394587A CA1182811A CA 1182811 A CA1182811 A CA 1182811A CA 000394587 A CA000394587 A CA 000394587A CA 394587 A CA394587 A CA 394587A CA 1182811 A CA1182811 A CA 1182811A
- Authority
- CA
- Canada
- Prior art keywords
- fragment
- iic
- tetanus toxin
- thiolated
- toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 120
- 108010055044 Tetanus Toxin Proteins 0.000 title claims abstract description 46
- 229940118376 tetanus toxin Drugs 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000008569 process Effects 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 title abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 36
- 229920001184 polypeptide Polymers 0.000 title abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 35
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 230000009844 retrograde axon cargo transport Effects 0.000 claims description 3
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 claims description 3
- JCERQDSYEXAYTH-UHFFFAOYSA-N 4-methylsulfanylbutanamide Chemical compound CSCCCC(N)=O JCERQDSYEXAYTH-UHFFFAOYSA-N 0.000 claims 1
- NRFJZTXWLKPZAV-UHFFFAOYSA-N N-(2-oxo-3-thiolanyl)acetamide Chemical compound CC(=O)NC1CCSC1=O NRFJZTXWLKPZAV-UHFFFAOYSA-N 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- 229960004753 citiolone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 26
- 210000002569 neuron Anatomy 0.000 abstract description 6
- 230000001962 neuropharmacologic effect Effects 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 239000003053 toxin Substances 0.000 description 19
- 231100000765 toxin Toxicity 0.000 description 18
- 108700012359 toxins Proteins 0.000 description 18
- 238000006177 thiolation reaction Methods 0.000 description 15
- 238000010168 coupling process Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000032258 transport Effects 0.000 description 12
- 206010043376 Tetanus Diseases 0.000 description 11
- 210000002182 synaptic membrane Anatomy 0.000 description 11
- 230000008878 coupling Effects 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000003376 axonal effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000007441 retrograde transport Effects 0.000 description 8
- 206010029216 Nervousness Diseases 0.000 description 7
- 108090000526 Papain Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 125000005414 dithiopyridyl group Chemical group 0.000 description 7
- 229940055729 papain Drugs 0.000 description 7
- 235000019834 papain Nutrition 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 150000002270 gangliosides Chemical class 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000008335 axon cargo transport Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000003565 oculomotor Effects 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 230000001379 nervous effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- REYLLNRLWCBKCM-YFKPBYRVSA-N (2s)-2-acetamido-4-sulfanylbutanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCS REYLLNRLWCBKCM-YFKPBYRVSA-N 0.000 description 1
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- QXDUMOMMZMHKOH-UHFFFAOYSA-N 2-sulfanylpentanamide Chemical compound CCCC(S)C(N)=O QXDUMOMMZMHKOH-UHFFFAOYSA-N 0.000 description 1
- IXHADCPJRQNDGG-UHFFFAOYSA-N 3-[bis(2-chloroethyl)amino]-1-(4-phenylphenyl)propan-1-one Chemical compound C1=CC(C(=O)CCN(CCCl)CCCl)=CC=C1C1=CC=CC=C1 IXHADCPJRQNDGG-UHFFFAOYSA-N 0.000 description 1
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- YUBJPYNSGLJZPQ-UHFFFAOYSA-N Dithiopyr Chemical compound CSC(=O)C1=C(C(F)F)N=C(C(F)(F)F)C(C(=O)SC)=C1CC(C)C YUBJPYNSGLJZPQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001517310 Eria Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101150114843 Mgll gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- 101710126507 Toxin 5 Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003948 anatoxin Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- -1 ide compound Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940028870 thiola Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940048910 thiosulfate Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8101176 | 1981-01-22 | ||
| FR8101176A FR2498192A2 (fr) | 1981-01-22 | 1981-01-22 | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000455021A Division CA1183775A (en) | 1980-09-13 | 1984-05-24 | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1182811A true CA1182811A (en) | 1985-02-19 |
Family
ID=9254407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000394587A Expired CA1182811A (en) | 1981-01-22 | 1982-01-21 | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4479940A (enExample) |
| EP (1) | EP0057140B1 (enExample) |
| JP (1) | JPS57176916A (enExample) |
| CA (1) | CA1182811A (enExample) |
| DE (1) | DE3264703D1 (enExample) |
| ES (2) | ES508935A0 (enExample) |
| FR (1) | FR2498192A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59116229A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
| JPS59116232A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体及びその製造法 |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| IL69558A (en) * | 1983-08-23 | 1988-06-30 | Yeda Res & Dev | Synthetic cholera vaccine |
| US4666884A (en) * | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| FR2567521B1 (fr) * | 1984-07-13 | 1987-01-02 | Sanofi Sa | Nouveaux ionophores actives |
| CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
| US6022950A (en) * | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| FR2575160B1 (fr) * | 1984-12-21 | 1987-03-20 | Sanofi Sa | Composes ionophores carboxyliques monovalents |
| US4762710A (en) * | 1986-06-16 | 1988-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Novel method of preparing toxoid by oxidation and metal ions |
| US5084559A (en) * | 1987-03-27 | 1992-01-28 | Repligen Corporation | Protein a domain mutants |
| US5601826A (en) * | 1989-06-30 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
| US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| GB9020075D0 (en) | 1990-09-14 | 1990-10-24 | Filler Aaron G | Contrast agents for magnetic resonance imaging of axonal transport |
| US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
| US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| EP1681300A1 (en) * | 1997-08-14 | 2006-07-19 | Institut Pasteur | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the CNS |
| US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
| US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
| US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
| US6258774B1 (en) * | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
| US20070092449A1 (en) * | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
| ES2332628B1 (es) * | 2007-10-05 | 2011-01-24 | Universidad De Zaragoza | Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2938023A (en) * | 1957-04-17 | 1960-05-24 | Hoechst Ag | Manufacture of glutathione containing mercapto groups |
| US3171831A (en) * | 1961-02-14 | 1965-03-02 | Schwarz Biores Inc | Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine |
| DE1617880A1 (de) * | 1966-10-06 | 1971-07-22 | Karl Dr Med Theurer | Verfahren zur Gewinnung von organotropen,bioaktiven Wirkstoffen,insbesondere von Arzneimitteln |
| DE2355094C3 (de) * | 1973-11-03 | 1979-05-23 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tetanus-Impfstoffs |
| IN140168B (enExample) * | 1974-10-14 | 1976-09-25 | All India Inst Med | |
| JPS5272284A (en) * | 1975-12-12 | 1977-06-16 | Dainippon Pharmaceutical Co | Enzymeeimmunoassay reagent |
| JPS5341420A (en) * | 1976-09-29 | 1978-04-14 | Mochida Pharm Co Ltd | Immunochemically measuring methoa of hapten |
| US4315031A (en) * | 1977-09-01 | 1982-02-09 | Science Union Et Cie | Thiosubstituted amino acids |
| FR2470773B1 (enExample) * | 1979-11-28 | 1983-01-28 | Pasteur Institut | |
| US4284624A (en) * | 1980-05-02 | 1981-08-18 | E. R. Squibb & Sons, Inc. | Mixed disulfides |
-
1981
- 1981-01-22 FR FR8101176A patent/FR2498192A2/fr active Granted
-
1982
- 1982-01-21 CA CA000394587A patent/CA1182811A/en not_active Expired
- 1982-01-21 ES ES508935A patent/ES508935A0/es active Granted
- 1982-01-21 US US06/341,335 patent/US4479940A/en not_active Expired - Fee Related
- 1982-01-21 DE DE8282400115T patent/DE3264703D1/de not_active Expired
- 1982-01-21 EP EP82400115A patent/EP0057140B1/fr not_active Expired
- 1982-01-22 JP JP57007770A patent/JPS57176916A/ja active Pending
-
1983
- 1983-02-01 ES ES519456A patent/ES519456A0/es active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES8306714A1 (es) | 1983-06-01 |
| EP0057140B1 (fr) | 1985-07-17 |
| EP0057140A3 (en) | 1982-08-25 |
| ES8400736A1 (es) | 1983-11-01 |
| FR2498192B2 (enExample) | 1983-09-09 |
| EP0057140A2 (fr) | 1982-08-04 |
| FR2498192A2 (fr) | 1982-07-23 |
| JPS57176916A (en) | 1982-10-30 |
| US4479940A (en) | 1984-10-30 |
| ES508935A0 (es) | 1983-06-01 |
| DE3264703D1 (en) | 1985-08-22 |
| ES519456A0 (es) | 1983-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1182811A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications | |
| US4340535A (en) | Cytotoxic products formed by covalent bonding of the A chain of ricin with an antibody and the process for their preparation and use | |
| Hannestad et al. | Cell-bound myeloma proteins on the surface of myeloma cells: potential targets for the immune system | |
| DK166966B1 (da) | Analogifremgangsmaade til fremstilling af immunoenzymatiske konjugater | |
| AU659427B2 (en) | Site-specific conjugation of immunoglobulins and detectable labels | |
| Paul et al. | STUDIES ON THE EFFECT OF THE CARRIER MOLECULE ON ANTIHAPTEN ANTIBODY SYNTHESIS: II. Carrier Specificity of Anti-2, 4-Dinitrophenyl-Poly-l-Lysine Antibodies | |
| US4594336A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application | |
| EP0015059B1 (en) | Immunochemical conjugates: method and composition | |
| Paoletti et al. | An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. | |
| Simpson et al. | Binding of streptococcal lipoteichoic acid to the fatty acid binding sites on serum albumin. | |
| Rask et al. | Isolation and properties of a murine spleen cell Fc receptor | |
| CA1183775A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for its obtention and its applications | |
| Rodrigues et al. | Immunity to Hemophilus Influenzae Type b: I. The Isolation, and Some Physicochemical, Serologic and Biologic Properties of the Capsular Polysaccharide of Hemophilus Influenzae Type b | |
| Jansen et al. | High specific cytotoxicity of antibody-toxin hybrid molecules (immunotoxins) for target cells | |
| US4276206A (en) | Immunochemical conjugates: method and composition | |
| DE4240056A1 (de) | Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper | |
| Beachey et al. | Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem. | |
| Hsu et al. | Fluorescent, electron microscopic, and immunoelectrophoretic studies of labeled antibodies | |
| JPH0276824A (ja) | ヘモフイルス・インフルエンザｂ型の酸化された多糖体―外層膜蛋白質複合体ワクチン | |
| US4900660A (en) | Streptococcal fc rc | |
| US4843147A (en) | Anhydrous enhanced coupling of proteins | |
| CA1152493A (en) | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications | |
| Sero et al. | Biological activity and complementation of the two peptides of staphylococcal enterotoxin B formed by limited tryptic hydrolysis. | |
| Forrester et al. | Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75 | |
| Myers et al. | Specific chemical cleavage of diphtheria toxin with hydroxylamine. Purification and characterization of the modified proteins. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |